Antibodies for the prevention or the treatment of bleeding episodes

US10544231B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITÉ PARIS-SUD · DE
• Centre Hospitalier Regional et Universitaire de Lille (CHRU) · FR
• UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 · FR

Inventors

• Petrus Lenting · Blois, FR
• Cecile Denis · Le Kremlin-Bicêtre, FR
• Olivier Christophe · Le Kremlin-Bicêtre, FR
• Paulette Legendre · Le Kremlin-Bicêtre, FR
• Antoine RAUCH · Lille, FR
• Sophie SUSEN · Lille, FR

Key dates

• Filing date: Apr 16, 2015
• Grant date: Jan 28, 2020
• Expiry date: Jun 23, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).